RUNCORN, United Kingdom – Epredia, a global leader in precision cancer diagnostics and a subsidiary of PHC Holdings Corporation (TSE: 6523), has entered into a distribution agreement with Mindpeak to bring artificial intelligence (AI)-powered image recognition software to pathology laboratories across the European Union. The collaboration aims to address increasing cancer cases and the growing complexity of diagnostic processes by accelerating workflows and reducing costs, according to a press release issued February 24, 2026.
The agreement will see Epredia integrate Mindpeak’s AI modules into its digital pathology portfolio, offering enhanced precision and speed in diagnostic image review. Pathology labs are facing mounting pressure to improve efficiency, and this partnership represents a significant step towards leveraging AI to meet those demands. The increasing incidence of cancer globally, coupled with advancements in diagnostic technologies, is driving the need for innovative solutions like those offered by Epredia and Mindpeak.
Mindpeak’s technology provides pixel-level analysis of digital images of tissue samples, enabling objective and reproducible assessments in several key areas of cancer diagnostics, including breast cancer, lung cancer, and gastrointestinal pathology. The AI tools also support biomarker quantification and exploratory research studies. A key benefit of the Mindpeak system is its ability to operate without cloud connectivity, addressing data privacy and security concerns for both clinical and research environments. This feature is increasingly important as data protection regulations become more stringent across Europe.
AI-Powered Image Recognition in Cancer Diagnostics
The AI software is designed to reduce variability in image analysis, support clinical decision-making, and improve overall workflow efficiency. According to the companies, the technology delivers instant analysis, allowing pathologists to focus on complex cases requiring their expertise. The distribution agreement covers a range of both CE Marked and research-use-only modules from Mindpeak, providing a comprehensive suite of AI tools for pathology labs. Epredia plans to explore integrating Mindpeak’s AI solutions into its E1000 Dx Digital Pathology Solution workflow in the future, aiming for seamless data exchange and streamlined processes.
Epredia’s E1000 Dx Digital Pathology Solution, which received U.S. Food and Drug Administration (FDA) 510(K) clearance in March 2025, is a high-speed, automated whole-slide imaging digital scanner capable of processing up to 1,500 tissue samples daily according to Epredia. The system features algorithm-based sample detection and dual slide processing to maximize throughput and efficiency. It also includes a quality control feature that automatically triggers a rescan if needed, ensuring high image quality for pathologist review.
PHC Group and Epredia’s Expanding Portfolio
Epredia was established in July 2019 through an acquisition by PHC Group from Thermo Fisher Scientific as detailed on the company’s website. The company focuses on enhancing precision diagnostics through a range of histology instruments, including the Revos Rotational Tissue Processor and the SlideMate Laser printer. PHC Holdings Corporation, Epredia’s parent company, is listed on the Tokyo Stock Exchange under the ticker symbol TSE: 6523.
This distribution agreement builds on Epredia’s recent FDA clearance for the E1000 Dx and demonstrates the company’s commitment to innovation in digital pathology. The partnership with Mindpeak further strengthens Epredia’s position as a leading provider of solutions for cancer diagnostics, offering a comprehensive portfolio of hardware, software, and AI-powered tools.
What to Watch Next
The initial rollout of Mindpeak’s AI modules through Epredia will focus on the European Union market. The companies will be closely monitoring the impact of the technology on laboratory workflows and diagnostic accuracy. Future developments will likely include further integration of Mindpeak’s AI solutions into the Epredia E1000 Dx platform, potentially creating a fully integrated digital pathology workflow. The success of this partnership could pave the way for similar collaborations in other regions as demand for AI-powered diagnostics continues to grow.
Share your thoughts on the future of AI in pathology in the comments below.
